DrugPatentWatch Database Preview

Details for Patent: 9,345,714

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,345,714 protect, and when does it expire?

Patent 9,345,714 protects CIPRODEX and is included in one NDA.

This patent has nineteen patent family members in sixteen countries.

Summary for Patent: 9,345,714

Title:	Method of treating middle ear infections
Abstract:	Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Inventor(s):	Wall; G. Michael (Fort Worth, TX), Conroy; Peter J. (Fort Worth, TX)
Assignee:	Alcon Pharmaceuticals Ltd. (Fribourg, CH)
Application Number:	14/838,637
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,345,714
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 9,345,714

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	CIPRODEX	ciprofloxacin; dexamethasone	SUSPENSION/DROPS;OTIC	021537-001	Jul 18, 2003	AB	RX	Yes	Yes			Y			TREATMENT OF ACUTE OTITIS MEDIA

International Family Members for US Patent 9,345,714

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	313328
Australia	2002333671
Brazil	0212898
Canada	2459930
China	1231218
China	1555267
Germany	60208216